[1] |
Kelly PJ, Archbold P, Price JH, et al. Serum CA19-9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype[J]. J Clin Pathol, 2010, 63:169-173.
|
[2] |
Tamakoshi K, Kikkawa F, Shibata K, et al.Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor[J]. Gynecol Oncol, 1996, 62:67-72.
|
[3] |
Coumbos A, Sehouli J, Chekerov R, et al. Current management of borderline ovarian tumors: A multicenter survey of 323 clinics in Germany, on behalf of the North-Eastern German Society of Gynecological Oncology (NOGGO)[J]. Br J Cancer, 2009, 100 (11):1731-1738.
|
[4] |
Hart WR. Borderline epithelial tumors of the ovary[J]. Mod Pathol, 2005, 18:S33-S50.
|
[5] |
Gultekin E, Gultekin OE, Cingillioglu B, et al. The value of frozen section evaluation in the management of borderline ovarian tumors[J]. J Cancer Res Ther, 2011, 7(4)416-420.
|
[6] |
Ren JPZ, Yang K. A clinicopathologic multivariate analysis affecting recurrence of borderline ovarian tumors[J]. Gynecologic Oncology, 2008, 110 (2):162-167.
|
[7] |
Tsai HW, Twu NF, Yeh CC, et al. Unilateral salpingo-oophorectomy as fertility-sparing surgery for borderline ovarian tumors[J]. J Chin Med Assoc, 2011, 74:250-254.
|
[8] |
Lenhard MS, Mitterer S, Kumper C, et al. Long-term follow-up after ovarian borderline tumor:Relapse and survival in a large patient cohort[J]. Eur J Obstet Gynecol Reprod Biol, 2009, 145:189-194.
|
[9] |
DeIaco P, Ferrero A, Rosati F, et al. Behaviour of ovarian tumors of low malignant potential treated with conservative surgery[J]. Eur J Surg Oncol, 2009, 35(6):643-648.
|
[10] |
Viganò R, Petrone M, Pella F, et al. Surgery in advanced borderline tumors[J]. Fertil Steril, 2010, 94(3):1163-1165.
|
[11] |
Palomba S, Falbo A, Del Negro S, et al. Ultra-conservative fertility-sparing strategy for bilateral borderline ovarian tumours: An 11-year follow-up[J]. Hum Reprod, 2010, 25(8):1966-1972.
|
[12] |
Morice P, Denschlag D, Rodolakis A, et al. Recommendations of the fertility task force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors[J]. Int J Gynecol Cancer, 2011, 21(5):951-963.
|
[13] |
Qiu F, Tan X, Wang YJ, et al. Reproductive prognosis after conservative treatments of borderline ovarian tumors and malignant ovarian tumors[J/CD].Chin J Obstet Gynecol Pediatr:Electron Ed, 2010, (01):58-61.
|
[14] |
Cao ZY.A guide to diagnosis and treatment of gynecological tumors.3rd ed[M]. Beijing:People's Medical Publishing House, 2009 83-85.
|
[15] |
van Leeuwen FE, Klip H, Mooij TM, et al.Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort[J]. Human Reprod, 2011, 26 (12):3456-3465.
|
[16] |
Sevcik L, Klat J, Koliba P, et al. Radical surgical therapy and role of adjuvant chemotherapy in ovarian tumors of borderline malignancy[J]. Cesk Gynek, 2004, 69:488-492.
|
[17] |
Suh-Burgmann E. Long-term outcomes following conservative surgery for borderline tumor of the ovary: A large population-based study[J]. Gynecol Oncol, 2006, 103(3):841-847.
|